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Abstract
Inhibition of the immunoproteasome (iCP) offers new opportunities in the treatment of cancer, autoimmune disorders and 
neurodegenerative diseases. Inspired by the success of boronic acids as proteasome inhibitors we have complied a virtual library of 
commercially available 5- and 6-membered borocycles and performed a structure based virtual screening against the chymotrypsin-
like (β5i) subunit of the iCP. The top scored docking poses were visually inspected to select compounds for experimental testing. 
Six compounds with 5-membered ring and another six compounds with 6-membered ring were subjected to biochemical tests. 
All compounds exhibited detectable inhibitory activity at 100 µM concentration and these are the first reported cyclic boronic acid 
inhibitors of the iCP. Structural variations including the ring size and the substitution of the borocyles and the substitution pattern of 
the attached aromatic ring resulted in no major variation of the inhibitory activity. We propose that the evaluation of larger cycling 
boronic acid libraries is needed to fully elucidate the potential of these structures.
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1 Introduction
The proteasome is a multiprotein complex which has mul-
ticatalytic properties. It assists in the degradation of dam-
aged proteins into short peptide sequences and represents 
the crucial part of the ubiquitin-proteasome system [1–4]. 
It has proven to be a valuable pharmacological target for 
the treatment of various disorders such as cancer, inflam-
mation and immune diseases [5, 6].
The proteasome can be divided into two parts: the 19S 
regulatory particle (19S RP) and the 20S catalytic core 
particle (20S CP). The latter consists of four heptameric 
rings, two internal β-rings and two external α-rings. Three 
β-rings are responsible for the catalytic activities, which 
are executed by the β1 (caspase-like), the β2 (trypsin-like), 
and the β5 (chymotrypsin-like) subunits [1–4].
The immunoproteasome (iCP) is an isoform of the 20S 
CP. It is expressed in response to a viral infection or after 
stimulation by pro-inflammatory cytokines, such as inter-
feron γ [3]. In the immunoproteasome, β1i, β2i and β5i sub-
units are incorporated into internal β-ring instead of con-
stitutive subunits. Selective inhibition of the iCP offers new 
opportunities in the treatment of inflammation and auto-
immune diseases, hematologic malignancies and in several 
neurological diseases, where neuroinflammation is a hall-
mark of disease progression [3, 6]. Several inhibitors of the 
iCP were reported to date; however, of the majority have 
peptidic structures, which result in poor pharmacokinetic 
properties in most of the cases. Another notable issue is the 
limited selectivity against the CP [1, 6].
Despite that boronic acids are known in chemical litera-
ture since the 19th century, growing interest towards these 
structures can be witnessed in the last few decades [7]. 
Not only they act as important reagents in synthetic chem-
istry (Suzuki-coupling [8], Chan-Lam coupling [9], Petasis 
reaction [10], etc.), different kinds of boronic acids have been 
subject to intensive research in medicinal chemistry [11].
Boronic acid-based inhibitors have been reported for 
several enzymes. These are predominantly, but not exclu-
sive, serine proteases, and the covalent binding to the cat-
alytic serine residue has been proved or can be hypothe-
sized [12]. Nowadays, significant efforts are devoted to the 
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design, synthesis and screening of boronic acid libraries. 
Dozens of hits against various targets were identified and 
a few drug discovery projects resulted in FDA-approved 
drugs (Table 1). For further insights into this topic, the 
reader is referred to excellent reviews focusing on boronic 
acids in medicinal chemistry [7, 11].
A large number of boronic acids have been investigated 
as CP and iCP inhibitors and bortezomib (Table 1) has been 
approved by FDA for the treatment of multiple myeloma. 
Inspired by the success of boronic acids as immunoprotea-
some inhibitors we have initiated a hit finding campaign with 
the objective of discovering cyclic boronic acids as inhib-
itors of the β5i subunit of iCP. This type of compounds 
is well known by medicinal chemists, and three cyclic 
boronic acid drugs have been approved by the FDA recently 
(Table 1). These include vaborbactam, a β-lactamase inhib-
itor, tavaborole, a leucyl-tRNA synthetase inhibitor, and 
crisaborole, a phosphodiesterase-4 inhibitor. Several other 
borocycles acting as β-lactamase inhibitors were identi-
fied [16–19], and Imperio et al. reported cyclic boronic acid 
sugar analogues which could function as potential agents in 
boron neutron capture therapy [20]. Nevertheless, to the best 
of our knowledge, no cyclic boronates were investigated as 
iCP inhibitors until the present work.
2 Methods
2.1 General chemistry methods
Compounds 1, 2, 3, 4, 5, and 7 were purchased from 
Enamine Ltd, compounds 6, 8, 9, 10, 11, and 12 were pur-
chased from Chemspace and all were used for biochemi-
cal screening as supplied. 1H and 13C NMR spectra were 
recorded on a Bruker Avance III 400 MHz spectrometer 
at 295 K. The chemical shifts (δ) are reported in parts per 
million (ppm) and are referenced to the deuterated solvent 
used. The coupling constants (J) are given in Hz, and the 
splitting patterns are designated as follows:
• s: singlet;
• d: doublet;
• dd: double doublet;
• t: triplet;
• td: triplet of doublets;
• m: multiplet.
Analytical reversed-phase HPLC was performed on 
Thermo Scientific Dionex UltiMate 3000 UHPLC modu-
lar system, equipped with a photodiode array detector set 
to 254 nm. An Acquity UPLC® BEH Shield RP18 Column 
(2.1 × 100 mm; 1.7 μm) was used, thermostated at 40 °C, 
and flow rate was set to 0.3 mL/min. Compound solutions 
Table 1 FDA-approved drugs containing boronic acid moiety
Structure INN Indication Remark
Bortezomib multiple myeloma proteasome inhibitor, approved in 2005 [13]
Ixazomib multiple myeloma orally bioavailable proteasome inhibitor, approved in 2015 [14]
Vaborbactam bacterial infections β-lactamase inhibitor, used in combination with meropenem, approved in 2017 [11]
Tavaborole onychomycosis antifungal agent, approved in 2014 [15]
Crisaborole eczema Phosphodiesterase-4 inhibitor, approved in 2016 [11]
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were prepared as 0.5 mM in MeCN with 5 % DMSO, 1 μL 
of which was injected. For the determination of stability, 
0.5 mM compound was incubated for 18 h in buffer (50 mM 
TRIS-Cl, 0.5 mM EDTA, pH 7.4, 2 % DMSO). After the 
incubation, 1 μL of this solution was injected. An elu-
ent system of A (0.1 % TFA in H2O) and B (MeCN) was 
used with gradient elution: 0–10 min, 5 % B → 80 % B; 
10–12 min, 80 % B; 12–12.5 min, 80 % B → 5 % B.
2.2 1H NMR and HPLC analyses of compounds
N-((2,2-difluorocyclopentyl)methyl)-1-hydroxy-1,3-dihy-
drobenzo[c][1,2]oxaborole-6-carboxamide (1): 1H NMR 
( 400 MHz, DMSO-d6 ) δ 9.30 (s, 1H, BOH), 8.56 (t, 
J = 5.6 Hz, 1H, NH), 8.20 (d, J = 0.9 Hz, 1H, Ar-H), 7.91 
(dd, J = 8.0, 1.7 Hz, 1H, Ar-H), 7.49 (d, J = 8.0 Hz, Ar-H), 
5.04 (s, 2H, CH2 ), 3.50 – 3.24 (m, 2H, CH2 , overlap 
with residual water peak), 2.23 – 1.43 (m, 7H, 3 × CH2 , 




1H NMR ( 400 MHz, DMSO-d6 ) δ 9.47 (s, 1H, BOH), 8.40 
(s, 1H, Ar-H), 7.96 (d, J = 2.3 Hz, 1H, Ar-H), 7.67 (dd, 
J = 8.2, 2.3 Hz, 1H, Ar-H), 7.29 – 7.23 (m, 2H, 2 × Ar-H), 
7.20 – 7.12 (m, J = 8.3 Hz, 4H, 3 × Ar-H), 5.72 (s, 1H), 4.05 
(t, J = 5.9 Hz, 2H, CH2CH2OB), 2.82 (t, J = 5.8 Hz, 2H, 
CH2CH2OB), 2.79 – 2.70 (m, td, 1H, overlap), 2.48 – 2.37 
(m, td, 1H, overlap with residual water peak), 2.04 (td, 
J = 13.0, 4.7 Hz, 1H), 1.81 (td, J = 13.0, 4.6 Hz, 1H), 1.39 
( s, 3H, CH3 ); purity by HPLC: 97.0 %; stability in buffer: 
99.8 % after 18 h.
2.3 Residual activity determination
The biochemical screening of compounds was performed 
at 100 µM final concentrations in assay buffer (0.01 % 
SDS, 50 mM Tris-HCl, 0.5 mM EDTA, pH 7.4). To each 
compound, 0.2 nM human iCP (Boston Biochem, Inc., 
Cambridge, MA, USA) was added and incubated for 
30 min at 37 °C. Afterwards, the reaction was initiated 
by the addition of Suc-LLVY-AMC (Bachem, Bubendorf, 
Switzerland) at 25 µM final concentration. This substrate 
was used to monitor the residual activity of the β5i sub-
unit of the iCP. The reaction progress was recorded on the 
BioTek Synergy HT microplate reader by monitoring flu-
orescence at 460 nm (λex = 360 nm) for 90 min at 37 °C. 
The initial linear ranges were used to calculate the veloc-
ity and to determine the residual activity.
2.4 Virtual screening
Commercially available borocycles were collected from 
eMolecules [21] building blocks and screening com-
pounds. LigPrep by Schrödinger [22] was used to gen-
erate 3D conformations, tautomeric and ionization states 
from SMILES codes at pH 6–8, while retaining specified 
chiralities. The X-ray structure deposited as PDB entry 
6E5B [23] was used for the virtual screening. The bind-
ing site is defined by the K and L chains, so all other 
chains were removed, as well as the covalently bound 
ligand. Protein Preparation Wizard [24, 25] was used to 
add hydrogen atoms, protonate residues at pH 7, refine the 
H-bond network and to perform a restrained minimiza-
tion. The receptor’s grid box required for docking calcu-
lations was centered on the corresponding co-crystallized 
ligand. Covalent docking was performed with CovDock 
program of the Schrödinger suite [22]. The pose predic-
tion mode [26] with default setup was applied. The top 
scored docking poses were visually inspected to select 
compounds for experimental testing.
3 Results and discussion
The compounds selected for virtual screening were cyclic 
boronic acids with 5- and 6-membered rings as shown 
in Fig. 1.
304 and 100 compounds with 5- and 6-membered ring, 
respectively, were collected (Table S1 and Table S2 in the 
Supplement). Their covalent docking to the Thr1 resi-
due of the β5i subunit of iCP resulted in various poses. 
Compounds that were oriented outward the binding site 
were not considered as potential hits. Several docked com-
pounds adopted a binding mode resembling that of Ro19 
(PDB: 5M2B), a non-peptidic β5i-selective inhibitor of 
human iCP [27]. These compounds oriented toward the 
Table S1 binding pocket whose different size in iCP and 
CP was proposed to be responsible for subtype selectiv-
ity [27]. Some other compounds adopted a position similar 
to that of peptid-like ligands that fit into the binding channel 
with main chain H-bonds and protrude into the subpock-
ets by their sidechains. However, the docked cyclic boronic 
acids were unable to form the hydrogen bond pattern typical 
Fig. 1 General formula of the borocycles with 5- and 6-membered rings
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to peptide-like covalent ligands that are hydrogen bounded 
to Ser21 and Gly47 backbone amine and carbonyl, respec-
tively. The binding modes proposed by covalent docking 
for compounds 1 and 7 are shown in Fig. 2.
Six compounds with 5-membered ring and another 
six compounds with 6-membered ring were selected for 
β5i inhibition assays. The selection was made by visual 
inspection taking into account docking scores and diver-
sity of the selected compounds. The inhibitory activity 
was measured at 100 µM concentration and the residual 
activities are shown in Table 2.
All compounds exhibit detectable inhibitory activity 
at 100 µM concentration. The remaining enzyme activ-
ity was around 50 % suggesting IC50 values in the 100 µM 
range. The activities were fairly uniform for both the 5- 
and 6-membered borocycles with no apparent effect of 
the substituent of the aromatic ring. Out of the 12 com-
pounds, nine contain amide functional group as this moi-
ety was highly represented in the screened library owing 
to synthetic reasons. However, direct interaction between 
the amide group and the protein was observed only 
for some of the compounds in the docked binding mode. 
Fig. 2 Binding modes of compounds 1 (top) and 7 (bottom) as proposed by covalent docking. Cyclic boronic acid ligands are shown with grey 
carbon atoms in stick representation. The overlaid Ro19 (top) and bortezomib (bottom) ligands are shown with green carbon atoms in thin stick 
representation. Covalently labelled Thr1 is shown in ball-and-stick representation. See text for the discussion of the binding modes.
296|Kollár et al.Period. Polytech. Chem. Eng., 65(3), pp. 292–298, 2021
The inhibitory activities of compounds with substituents 
on the borocycle (compounds 2, 5, 10, and 11) did not show 
a clear trend either.
Compounds 1 and 7, which showed the strongest inhi-
bition with residual activities values below 40 % (Table 2) 
were further analysed by 1H NMR and HPLC to confirm 
their uniformity. In addition, buffer stability assay was 
performed for these two borocycles in order to evaluate 
the aqueous stability of the oxaborole (in compound 1) and 
oxaborinin (in compound 7) moieties. In both cases, the 
18 h treatment of compounds in the assay buffer did not 
chemically alter the compounds.
Although covalent inhibitors most often exhibit higher 
than micromolar affinity toward their target, the observa-
tion that the fairly diverse set of compounds with similar 
cyclic boronic acid warheads has similar activity suggests 
that reactivity is the primary determinant for inhibitory 
activity. Moreover, neither the reactivity nor the com-
pound recognition by the protein was significantly affected 
by the substitution pattern. Assuming covalent inhibition, 
the modest activity of these compounds suggests that 
either the electrophilicities of the cyclic boronic acid moi-
eties are low, or that these warheads are not placed in an 
optimal position with respect to the OH group of the cata-
lytic Thr1 in β5i active site. 
4 Conclusions
We investigated a set of cyclic boronic acids as inhibitors 
of the β5i subunit of the immunoproteasome. The bio-
chemical evaluation of twelve compounds selected by vir-
tual screening showed activities in the micromolar range. 
We believe that further work with borocycles as protea-
some inhibitors is warranted. Evaluations of larger librar-
ies of compound are needed to fully elucidate the potential 
of these structures as inhibitors of either CP or iCP.
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